A 3D View Targeting Inflammatory Cytokines: Addressing Articular and Systemic Pathology in Patients with Moderate-to-Severe Rheumatoid Arthritis
Andreas Reimold, MD
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle WA
University of Florence, Florence, Italy
This case-based online activity will cover the treatment and management of patients with moderate-to-severe rheumatoid arthritis.
This enduring activity is designed to meet the educational needs of primarily rheumatologists with a secondary audience of internists and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
Upon the completion of this program, attendees should be able to:
- Describe the role of inflammatory cytokines, both articulately and systemically, in the pathogenesis of rheumatoid arthritis
- Review the clinical trials data supporting the medical society pharmacologic recommendations for patients with moderate-to-severe rheumatoid arthritis
- Discuss the use of interleukin-6 inhibition as a treat-to-target strategy in patients with moderate-to-severe rheumatoid arthritis
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Andreas Reimold, MD, is a consultant for Lilly and receives research grants from AbbVie, Novartis, and Pfizer.
Daniel E. Furst, MD, has contracted research for AbbVie, Actelion, Amgen, BMS, Corbus, NIH, Novartis, Pfizer, and Roche/Genentech. Dr. Furst is on the speakers’ bureau for CMC Connect (McCann Health Company). He is a consultant with AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, and Roche/Genentech.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
David Chatman, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: November 13, 2018
EXPIRATION DATE: November 13, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.